Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Proton-linked monocarboxylate transporter. De plus, nous expédions SLC16A4 Protéines (4) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 21 products:
High MCT-4 expression is associated with clear cell renal cell carcinoma (Montrer MOK Anticorps).
Nrf2 (Montrer GABPA Anticorps) overexpression upregulated MCT1 (Montrer CMA1 Anticorps), but decreased MCT4 expression in premalignant and malignant colonic epithelial cells.
Elevated MCT4 protein expression in clinical prostate cancer specimens was associated with increases in Gleason grade, prolonged treatment of patients with neoadjuvant hormone therapy, castration resistant prostate cancer, and early disease relapse.
our finding that the expression of MCT1 (Montrer CMA1 Anticorps) and MCT4 is reduced in mutant IDH1 (Montrer IDH1 Anticorps) gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 (Montrer IDH1 Anticorps) tumors and has important implications for our understanding of these tumors and their treatment
Results suggest that MCT4 plays a central role in tumor metabolism in gastric cancer (GC) with peritoneal carcinomatosis and targeting MCT4 in combination with chemotherapy could be a novel strategy in the treatment of GC.
TOMM20 (Montrer TOMM20 Anticorps), MCT1 (Montrer CMA1 Anticorps), and MCT4 expression was significantly different in Hodgkin and Reed Sternberg (HRS) cells. High MCT4 expression was found in tumor associated macrophages, but absent in HRS cells in all but one case. Tumor-infiltrating lymphocytes had absent MCT4 expression. Reactive lymph nodes in contrast to cHL (Montrer CHRDL1 Anticorps) tumors had low TOMM20 (Montrer TOMM20 Anticorps), MCT1 (Montrer CMA1 Anticorps), and MCT4 expression in lymphocytes and macrophages.
Stromal cells in diffuse large B-cell lymphoma samples strongly expressed MCT4, displaying a glycolytic phenotype, a feature not seen in stromal elements of non-neoplastic lymphatic tissue.
MCT1 (Montrer CMA1 Anticorps) inhibitor AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux.
The reversible H(+)/lactate(-) symporter MCT4 cotransports lactate and proton, leading to the net extrusion of lactic acid in glycolytic tumors. A model of its role in pH control in tumor cells is described. Review.
Increased miR (Montrer MLXIP Anticorps)-210 and concomitant decreased ISCU (Montrer ISCU Anticorps) RNA levels were found in ~40% of tumors and this was significantly associated with HIF-1alpha (Montrer HIF1A Anticorps) and CAIX (Montrer CA9 Anticorps), but not MCT1 (Montrer CMA1 Anticorps) or MCT4, over-expression.
This study showed that mouse MCT1 (Montrer MCTS1 Anticorps), MCT2 (Montrer SLC16A7 Anticorps), and MCT4 (Montrer SLC16A3 Anticorps) are expressed in the PNS. While DRG neurons express MCT1 (Montrer MCTS1 Anticorps), myelinating Schwann cells.
Expression of cerebral MCT (Montrer MCAT Anticorps) isoforms can be modulated by alterations of peripheral metabolism, suggesting that the adult brain is sensitive and adapts to new metabolic states.
Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).
, MCT 5
, monocarboxylate transporter 4
, monocarboxylate transporter 5
, solute carrier family 16 (monocarboxylic acid transporters), member 4
, solute carrier family 16, member 4 (monocarboxylic acid transporter 5)
, solute carrier family 16, member 4
, LOW QUALITY PROTEIN: monocarboxylate transporter 5